CEBPZ and acute myeloid leukemia: Despite the great clinical improvements that have been made in the treatment of AML, t(8;21)-associated CBF AML remains a significant clinical problem, with 30% of patients relapsing and long-term survival rates ranging between 61 and 31% (Appelbaum et al, 2006; Döhner et al, 2010; Grimwade et al, 2010; Lin et al, 2008; Marcucci et al, 2005; Narimatsu et al, 2008).